Iceland· IS-EU/1/19/1411/003-004
Evenity
A romosozumab product containing romosozumabum inn, registered in Iceland by UCB Pharma S.A.*. The same ATC class is registered in 15 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Romosozumab is registered in 15 of 19 countries.
Countries holding a registration under ATC M05BX06 (romosozumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 10 of them publish a price we can compare per daily dose
Romosozumab · ATC M05BX06
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of romosozumab costs, country by country.
Normalised to the WHO defined daily dose (7 mg), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Romosozumab · price per daily dose (7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$19.87
- ES Spain$17.72
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Romosozumabum INN
- Manufacturer
- UCB Pharma S.A.*
- Country
- Iceland (IS)
- ATC code
- M05BX06
- ATC class
- Romosozumab
- Defined daily dose
- 7 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean9643262 stk x1 þpakkiISK 127219
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
53 interactions on record for romosozumab.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Romosozumab · interactions on record
53 records
- 1 severe
- 52 moderate
Most severe, free to view
- EtelcalcetideH05BX04severe
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- PrednisoneA07EA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Romosozumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEVENITYUCB Pharma SA, Brusel
- BelgiumEvenity 105 mgUCB Pharma
- SwedenEVENITY 105 mg Injektionsvätska, lösning i förfylld injektionspennaUCB Pharma S.A.
- SpainEVENITY 105 MG SOLUCION INYECTABLE EN PLUMA PRECARGADAUcb Pharma
- NorwayEvenityUCB Pharma S.A. (2)
- United StatesEvenityAmgen, Inc
- IrelandEVENITY 105 mg solution for injection in pre-filled penUCB Pharma S.A.
- FinlandEVENITYUCB Pharma SA
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Evenity
- Norway · Evenity
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7a1044cd-fb4f-4b07-a3b9-fa51c084daa2 GET /v1/drugs/7a1044cd-fb4f-4b07-a3b9-fa51c084daa2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn í áfylltri sprautu",
"source": "lyfjastofnun",
"atc_raw": "M05BX06",
"marketed": false,
"strength": "105 mg",
"ma_number": "EU/1/19/1411/003-004",
"substance": "Romosozumabum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í efnaskipta- og innkirtlalækningum - gigtarlækningum - bæklunarlækningum - öldrunarlækningum og almennum lyflækningum.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "43808"
}See everything about romosozumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.